Question

Care este rata de succes a terapiei cu celule stem pentru Durere de spate și degenerare discală?

Meaningful pain reduction (≥20% improvement on 0–100 pain scale) is reported in 50–65% of treated patients in published series. Functional improvement (return to work, reduced medication) occurs in 40–55% of responders. Imaging evidence of disc hydration improvement is present in 30–50% but does not always correlate with pain relief, suggesting mechanisms beyond structural regeneration. Patients with non-radicular, axial low back pain respond more favourably than those with significant radiculopathy. Treatment failure (no change or worsening) occurs in 20–30%, with no current biomarkers predicting responders.

Ce arată dovezile pentru Durere de spate și degenerare discală

Published trials of intradiscal placental MSC injection demonstrate pain reduction (VAS or Oswestry scales) in 50–65% of participants over 6–12 months. Discography MRI findings show improved hydration signals in 30–50% of treated discs, interpreted as proteoglycan restoration, though correlation with pain outcomes is inconsistent. One phase II trial (67 patients) reported sustained pain relief at 24-month follow-up in 55% of injected discs. Exosome intra-discal delivery is emerging with small proof-of-concept studies showing reduced inflammatory biomarkers in disc fluid post-injection. Comparative data versus sham injection remain limited; most positive evidence derives from open-label or non-blinded designs.

Sunt un candidat? → · Back Pain & Disc Degeneration: full overview → · Cost Durere de spate și degenerare discală → · Cost →

Revizuit medical de echipa editorială a StemCellAtlas cu Kiian Nadiia, MD, PhD (Paediatric Neurologist · Medical Director, CSM Clinic Network · 12+ yrs in Autism Spectrum Disorders) ale clinicii partenere Stem Plus (Sofia), în funcție de orientările ISSCR, FDA și EMA. Last reviewed 2026-07-23; see our editorial standards. Educational information, not medical advice; figures indicative.

Terapie celulară de nivel european, fără prețuri europene.

Medicină regenerativă certificată GMP în inima UE — de la 3.000–8.000 €, o fracțiune din prețurile din SUA sau Germania. Protocoale personalizate pentru pacienți din peste 50 de țări.

Evaluare medicală gratuită